A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Yang Xu, PhD
Head of US Clinical Development
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Sarah Cannon Research Institute at Healthone
Denver, Colorado, United States
- Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, Florida, United States
- Christ Hospital
Cincinnati, Ohio, United States
- Next Oncology
Austin, Texas, United States
- Mays Cancer Center
San Antonio, Texas, United States
- Next Oncology
Fairfax, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2022
- Primary completion
- 17 Jul 2024
- Completion
- 29 Jun 2026
- Last update posted
- 15 Dec 2025
- Registered enrollment
- 39
- Registry id
- NCT05159700
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.